NKGen Biotech Inc (NKGN) P/E multiplikatori
NKGen Biotech, Inc. (NKGN) qimmatli qog'ozlarining narxlar dinamikasi demensiyaga qarshi kurashish uchun NK-hujayralariga asoslangan terapiyalarni ishlab chiqish samaradorligini baholash imkonini beradi, bunda ko'rsatkich -0.10 darajasida turibdi. NKGen Biotech, Inc. (NKGN) o'zining raqamli intellektual mulkini himoya qilgan holda, AQSh va Janubiy Koreyada hujayrali mahsulotlarni yaratishga e'tibor qaratadi. Operatsion faoliyat biomateriallarni qayta ishlash bo'yicha qat'iy FDA tartib-qoidalariga tayanadi, bu esa ekologik xavfsizlikning bazaviy darajasini ta'minlaydi.
NKGen (NKGN) kompaniyasining tahliliy kesimlari
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi tafsilotlari:
- kompaniyaning balans qiymati tafsilotlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati NKGen Biotech, Inc.|NKGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati NKGen Biotech Corp|NKGN - Kompaniyaning jamlangan qarzlari|Qarzning balans kapitallashuviga nisbati NKGen Biotech, Inc.|NKGN - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi NKGen Biotech|Shoshilinch likvidlik nkgenbiotech.com
- foyda va multiplikatorlar bo'yicha ma'lumotlar:
NKGN - Sof daromad|Kelajakdagi sof foyda NKGen Biotech, Inc.|NKGN - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati NKGen Biotech Inc|NKGN - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti NKGen Biotech, Inc.|NKGN - EBITDA operatsion foydasi|Sirpanuvchi yil uchun bir aksiya uchun foyda NKGen Biotech|NKGN - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi nkgenbiotech.com|NKGN - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi NKGen Biotech, Inc.
- kompaniyaning sotuvlari va tushumi statistikasi:
Kompaniyaning jamlanma tahlili:nkgenbiotech.com
NKGen Biotech, Inc. (NKGN) AQSh va Janubiy Koreyada neyrodegenerativ patologiyalar uchun hujayra terapiyalarini ishlab chiqadi. Klinik sinovlarning samaradorligi sof foydaga bevosita ta'sir ko'rsatib, P/E koeffitsientini hisoblash uchun asos bo'lib xizmat qiladi. Ushbu koeffitsient foyda birligi uchun xarajatni belgilab, investorlarning bozor kutganlarini aks ettiradi. Yuqori qiymatlar kelajakdagi o'sish uchun premiumni anglatadi. NKGen Biotech, Inc. (NKGN) kompaniyasining P/E koeffitsienti grafigini tahlil qilish orqali, qat'iy pul-kredit siyosati sharoitida haddan tashqari ko'p to'lov qilish xavfini baholash mumkin.
Muhim raqobatchilar
Narx-foyda multiplikatori BIIB (biogen.com)|Narxning foydaga nisbati Neurocrine Biosciences, Inc. (NBIX)|P/E multiplikatori Regencell Bioscience Ltd (RGC)|P/E multiplikatori AXSM (Axsome Therapeutics Inc)|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti ACADIA Corp|Xenon Pharmaceuticals - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati vikingtherapeutics.com|Supernus (SUPN) - Narxning foydaga nisbati|Narx-foyda multiplikatori CPRX|Narx-foyda koeffitsiyenti DNLI|HRMY: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHVN|Narxning foydaga nisbati AMLX (amylyx.com)|P/E multiplikatori TRVI (Trevi Therapeutics, Inc.)|Biznesning o‘zini qoplash muddati Praxis Precision Medicines Inc (PRAX)|AVXL - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati CeriBell EEG|PRTA (prothena.com) - Narx-foyda koeffitsiyenti|ALEC: Bozor narxining sof foydaga nisbati|ANNX (Annexon) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Omeros Corp. OMER|P/E multiplikatori NGNE|Narx-foyda koeffitsiyenti AC Immune Inc ACIU|P/E multiplikatori VYGR (Voyager Therapeutics)|Kompaniya qiymatining sof foydaga nisbati NMRA|SCLX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati TVGN (Tevogen Bio Holdings Inc.)|ACOG: P/E multiplikatori|CGTX - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Inhibikase Therapeutics|Narx-foyda multiplikatori SAVA (cassavasciences.com)|P/E multiplikatori ASRT|Narx-foyda koeffitsiyenti coyatherapeutics.com COYA|Vistagen - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Ovid Therapeutics Inc (OVID)|ABOS - Narxning foydaga nisbati|CRVO (cervomed.com) - Narx-foyda multiplikatori|alteritytherapeutics.com (ATHE) - Narxning foydaga nisbati|Clene (CLNN) - P/E multiplikatori|PEPG (PepGen Inc) - P/E multiplikatori|JUNS - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati Relmada Therapeutics (RLMD)|annovisbio.com - Narx-foyda multiplikatori|Narxning foydaga nisbati Grace Therapeutics GRCE|AIFF: Narx-foyda multiplikatori|ANEW Medical, Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals) - Narx-foyda koeffitsiyenti|MetaVia (MTVA) - P/E multiplikatori|Narxning foydaga nisbati NeurAxis|HSDT: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Passage Bio, Inc. (PASG)|NEUP - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Minerva Neurosciences NERV|ATHA: Narx-foyda multiplikatori|ADXN - Narxning foydaga nisbati|ALZN - P/E multiplikatori|CYCN: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Protagenic Therapeutics, Inc. PTIX|KTTA (Pasithea Therapeutics Corp) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Cortigent Medical CRGT|Narxning foydaga nisbati Avenue Therapeutics, Inc. (ATXI)|Brainstorm Cell Therapeutics Inc. - Narx-foyda multiplikatori|Cara Therapeutics, Inc - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati CHRO|Eliem - P/E multiplikatori|ITCI: Narxning foydaga nisbati|LBPH: P/E multiplikatori|MRNS - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati NeuroBo|Kapitalizatsiyaning foydaga nisbati Sage Therapeutics Inc SAGE|Narx-foyda koeffitsiyenti SNPX (Synaptogenix, Inc.)|Bozor narxining sof foydaga nisbati TRVN|P/E multiplikatori VIGL (Vigil Neuroscience, Inc.)|anewmeds.com (WENA) - Kapitalizatsiyaning foydaga nisbati|Cerevel - P/E multiplikatori
